Stock Traders Buy High Volume of FibroGen Call Options (FGEN)

FibroGen Inc (NASDAQ:FGEN) was the recipient of some unusual options trading on Friday. Stock traders acquired 2,431 call options on the stock. This is an increase of 2,631% compared to the average volume of 89 call options.

FibroGen (NASDAQ FGEN) opened at $42.40 on Monday. FibroGen has a twelve month low of $19.25 and a twelve month high of $60.15. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16.

In other news, Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction on Tuesday, October 17th. The stock was sold at an average price of $52.24, for a total transaction of $104,480.00. Following the transaction, the director now directly owns 26,000 shares of the company’s stock, valued at approximately $1,358,240. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider K Peony Yu sold 2,851 shares of the stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $43.70, for a total value of $124,588.70. Following the transaction, the insider now directly owns 162,086 shares in the company, valued at $7,083,158.20. The disclosure for this sale can be found here. Insiders have sold a total of 344,346 shares of company stock worth $18,110,030 over the last three months. Insiders own 13.60% of the company’s stock.

A number of institutional investors have recently made changes to their positions in FGEN. Iguana Healthcare Management LLC bought a new stake in FibroGen during the third quarter valued at about $2,152,000. California Public Employees Retirement System raised its holdings in FibroGen by 1.8% during the third quarter. California Public Employees Retirement System now owns 94,900 shares of the biopharmaceutical company’s stock valued at $5,106,000 after acquiring an additional 1,700 shares during the period. Perceptive Advisors LLC bought a new stake in FibroGen during the third quarter valued at about $462,000. Jane Street Group LLC raised its holdings in FibroGen by 102.4% during the third quarter. Jane Street Group LLC now owns 17,613 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 8,910 shares during the period. Finally, BBR Partners LLC bought a new stake in FibroGen during the third quarter valued at about $299,000. 57.43% of the stock is currently owned by institutional investors.

A number of brokerages recently commented on FGEN. BidaskClub cut FibroGen from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. ValuEngine cut FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $80.00 target price on shares of FibroGen in a report on Thursday, September 14th. Mizuho began coverage on FibroGen in a report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 target price on the stock. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $75.00 target price on shares of FibroGen in a report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $65.67.

TRADEMARK VIOLATION WARNING: “Stock Traders Buy High Volume of FibroGen Call Options (FGEN)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2017/12/18/stock-traders-buy-high-volume-of-fibrogen-call-options-fgen.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply